SFDA Records 83 Percent Growth In Clinical Trials For Biotechnology In 2025

The Saudi Food and Drug Authority reported sharp growth in research activity for advanced therapies and biotechnology products in 2025. Clinical trial applications for these treatments rose by 83% compared with 2024. Early-stage clinical trials increased by 39%, signalling higher interest from sponsors. These changes place Saudi Arabia as a stronger location for global clinical research in the region.

The authority stated that about 2,700 patients in Saudi Arabia received access to innovative and advanced treatments through participation in these clinical trials. Patients came from different segments of society and disease areas. The SFDA said this participation helped improve healthcare outcomes, while also giving patients access to therapies that might otherwise be unavailable.

A key driver of this expansion has been the "Reliance Pathway for Clinical Trials". The SFDA explained that this pathway raised operational efficiency and cut approval timelines by 74% compared with the standard track. Faster approvals allow sponsors to launch studies more quickly. This supports earlier patient access to new medicines that comply with strict quality and safety requirements.

The SFDA stated that these regulatory measures are closely aligned with national objectives and Saudi Vision 2030. By supporting clinical trials in advanced therapies and biotechnology, the authority seeks to help diversify the national economy. The same efforts are intended to enhance quality of life, while drawing both domestic and international investment into the health and life sciences sectors.

According to the SFDA, the recent achievements also reflect cooperation with partners in public and private sectors. Together, these partners are working to build a strong research ecosystem that supports high-quality clinical trials. They aim to create conditions that encourage investment and ease the transfer of advanced biotechnology into Saudi Arabia’s healthcare system.

The Saudi Food and Drug Authority reaffirmed its commitment to a regulatory environment that supports research and innovation in clinical trials. The authority indicated that sustained progress in advanced therapies and biotechnology will depend on clear rules and efficient processes. These steps are expected to help maintain growth in studies and benefits for patients in Saudi Arabia.

With inputs from SPA